TREML1

Across TCGA pan-cancer cohorts, TREML1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of TREML1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TREML1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TREML1 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, LUAD, and HNSC are the cancer types where TREML1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TREML1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	+0.730	<.001	11	view →
LUAD	Male	All	−0.641	<.001	11	view →
HNSC	Female	II,III,IV	+0.467	<.001	11	view →
KIRP	Male	All	+0.880	<.001	9	view →
LUSC	Male	II,III,IV	−1.185	<.001	8	view →
STAD	All	All	+0.476	.003	4	view →
THCA	Male	IV	+0.470	.001	3	view →
CHOL	All	All	+0.363	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

TREML1–KIRC

Open the KIRC breakdown →